Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.

Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R, Stephan DA.

Cancer Res. 2005 Mar 1;65(5):1748-54.

2.

Primary bone osteosarcoma in the pediatric age: state of the art.

Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G.

Cancer Treat Rev. 2006 Oct;32(6):423-36. Epub 2006 Jul 24. Review.

PMID:
16860938
3.

Therapy for osteosarcoma: where do we go from here?

Chou AJ, Geller DS, Gorlick R.

Paediatr Drugs. 2008;10(5):315-27. Review.

PMID:
18754698
4.

Proteins expressed in osteosarcoma and serum levels as prognostic factors.

Trieb K, Kotz R.

Int J Biochem Cell Biol. 2001 Jan;33(1):11-7. Review.

PMID:
11167128
5.

Molecular classification of osteosarcoma.

Lau CC.

Cancer Treat Res. 2009;152:459-65. doi: 10.1007/978-1-4419-0284-9_26. Review.

PMID:
20213408
6.

[Place of the pathologist in the management of primary bone tumors (osteosarcoma and Ewing's family tumors after neoadjuvant treatment)].

Gomez-Brouchet A, Bouvier C, Decouvelaere AV, Larousserie F, Aubert S, Leroy X, Guinebretière JM, Coulomb A, Cassagnau E, de Muret A, Audard V, Marie B, de Pinieux G.

Ann Pathol. 2011 Dec;31(6):455-65. doi: 10.1016/j.annpat.2011.10.009. Epub 2011 Nov 29. Review. French.

PMID:
22172118
7.

Personalized care of pediatric cancer patients.

Rabin K, Man TK, Lau CC.

Nestle Nutr Workshop Ser Pediatr Program. 2008;62:173-85; discussion 185-8. doi: 10.1159/000146259. Review.

8.

Osteosarcoma and other tumors of bone.

Mertens WC, Bramwell V.

Curr Opin Oncol. 1994 Jul;6(4):384-90. Review.

PMID:
7803539
9.

A preliminary investigation of Beta-hCG expression in patients with osteosarcoma.

Masrouha KZ, Khattab R, Tawil A, Abdallah A, Saghieh S, Haidar R, Abboud M, Khoury NJ.

J Bone Joint Surg Br. 2012 Mar;94(3):419-24. doi: 10.1302/0301-620X.94B3.27679. Review.

PMID:
22371553
10.

Novel therapeutic agents for osteosarcoma.

O'Day K, Gorlick R.

Expert Rev Anticancer Ther. 2009 Apr;9(4):511-23. doi: 10.1586/era.09.7. Review.

PMID:
19374604
11.

Osteosarcoma occurring in osteogenesis imperfecta.

Takahashi S, Okada K, Nagasawa H, Shimada Y, Sakamoto H, Itoi E.

Virchows Arch. 2004 May;444(5):454-8. Review.

PMID:
15214333
12.

Osteosarcomas and other cancers of bone.

Bramwell VH.

Curr Opin Oncol. 2000 Jul;12(4):330-6. Review.

PMID:
10888418
13.

Osteosarcoma and other bone cancers.

Himelstein BP.

Curr Opin Oncol. 1998 Jul;10(4):326-33. Review.

PMID:
9702400
14.

Biology and therapeutic advances for pediatric osteosarcoma.

Marina N, Gebhardt M, Teot L, Gorlick R.

Oncologist. 2004;9(4):422-41. Review.

15.

Epigenetic changes in osteosarcoma.

Cui J, Wang W, Li Z, Zhang Z, Wu B, Zeng L.

Bull Cancer. 2011 Jul;98(7):E62-8. doi: 10.1684/bdc.2011.1400. Review.

16.

New targets and approaches in osteosarcoma.

Gill J, Ahluwalia MK, Geller D, Gorlick R.

Pharmacol Ther. 2013 Jan;137(1):89-99. doi: 10.1016/j.pharmthera.2012.09.003. Epub 2012 Sep 14. Review.

PMID:
22983152
17.

Drug sensitivity and resistance genes in cancer chemotherapy: a chemogenomics approach.

Huang Y, Sadée W.

Drug Discov Today. 2003 Apr 15;8(8):356-63. Review.

PMID:
12681939
18.

mRNA microarray analysis in lymphoma and leukemia.

Greiner TC.

Cancer Treat Res. 2004;121:1-12. Review.

PMID:
15217204
19.

Emerging drugs for high-grade osteosarcoma.

Hattinger CM, Pasello M, Ferrari S, Picci P, Serra M.

Expert Opin Emerg Drugs. 2010 Dec;15(4):615-34. doi: 10.1517/14728214.2010.505603. Epub 2010 Aug 9. Review.

PMID:
20690888
20.

Pathological diagnosis of osteosarcoma: the validity of the subclassification and some new diagnostic approaches using immunohistochemistry.

Ueda Y, Roessner A, Grundmann E.

Cancer Treat Res. 1993;62:109-24. Review. No abstract available.

PMID:
8096725

Supplemental Content

Support Center